Skip Navigation



European Heart Journal Advance Access published online on August 17, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm331
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/18/2185    most recent
ehm331v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Murphy, N. F.
Right arrow Articles by McDonald, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murphy, N. F.
Right arrow Articles by McDonald, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Treatment of anaemia in chronic heart failure—optimal approach still unclear

Niamh F. Murphy and Kenneth McDonald*

Heart Failure Unit, Department of Cardiology, St Vincent's University Hospital, and University College Dublin, Dublin 4, Ireland

* Corresponding author. Tel: + 353 1 2845735; fax: + 353 1 2304639. E-mail address: kenneth.mcdonald@ucd.ie

This editorial refers to ‘Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia’ by D. J. van Veldhuisen et al., doi:10.1093/eurheartj/ehm328

The first 10% of the full text of this article appears below.

Anaemia, most commonly defined using the WHO definition as a haemoglobin <13 g/dL in men and <12.0 g/dL in women, has variable prevalence in heart failure. Rates vary between 4 and 55% dependent on the population studied and the definition of anaemia used.1,2 Anaemia is more common in patients with NHYA functional class III or IV symptoms and in those with renal dysfunction.1 The increasing interest in this subject reflects the observations that have been made regarding the independent clinical impact of low haemoglobin in heart failure. The presence of anaemia is associated with worse symptoms, reduced exercise capacity, and an increased risk of hospital admission. In addition, anaemia also portends a worse prognosis, with a 2–3% increased risk of death per 1% reduction in haematocrit.3

A number of factors contribute to the pathogenesis of anaemia in heart failure. Expansion of blood volume can result . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
Dirk J. van Veldhuisen, Kenneth Dickstein, Alain Cohen-Solal, Dirk J.A. Lok, Scott M. Wasserman, Nigel Baker, Dylan Rosser, John G.F. Cleland, and Piotr Ponikowski
EHJ 2007 28: 2208-2216. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
A. Kazory and E. A. Ross
Anemia: the point of convergence or divergence for kidney disease and heart failure?
J. Am. Coll. Cardiol., February 24, 2009; 53(8): 639 - 647.
[Abstract] [Full Text] [PDF]

Home page
 ESC Textbook of Cardiovascular MedicineHome page
J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner
CHAPTER 23 Heart Failure
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]